Phase I study of L-alanosine (NSC 15353)
- 1 February 1983
- Vol. 51 (3) , 378-380
- https://doi.org/10.1002/1097-0142(19830201)51:3<378::aid-cncr2820510303>3.0.co;2-i
Abstract
L-alanosine (NSC I5353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. Experimental antitumor activity was demonstrated in a variety of murine neoplasms. A phase I trial was undertaken on a daily × 5 (d × 5) schedule in 22 evaluable patients. Dose limiting toxicity was an oral mucositis characterized by beefy red oral, lingual and pharyngeal erythema. The maximum tolerated dose is 320 mg/m2/d × 5 every three weeks. The recommended dose for phase II evaluation is 160 mg/m2/d × 5 every three weeks.This publication has 4 references indexed in Scilit:
- ALANOSINE TOXICITY IN NOVIKOFF RAT HEPATOMA-CELLS DUE TO INHIBITION OF CONVERSION OF INOSINE MONOPHOSPHATE TO ADENOSINE-MONOPHOSPHATE1976
- Alanosine and hadacidin—Comparison of effects on adenylosuccinate synthetaseBiochemical Pharmacology, 1968
- Effects of alanosine on purine and pyrimidine synthesisBiochemical Pharmacology, 1968
- Alanosine, a New Antiviral and Antitumour Agent isolated from a StreptomycesNature, 1966